Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs)
-
Published:2022-11-08
Issue:3
Volume:482
Page:463-475
-
ISSN:0945-6317
-
Container-title:Virchows Archiv
-
language:en
-
Short-container-title:Virchows Arch
Author:
Pisacane Alberto, Cascardi ElianoORCID, Berrino Enrico, Polidori Alessio, Sarotto Ivana, Casorzo Laura, Panero Mara, Boccaccio Carla, Verginelli Federica, Benvenuti Silvia, Dellino Miriam, Comoglio Paolo, Montemurro Filippo, Geuna Elena, Marchiò Caterina, Sapino Anna
Abstract
AbstractThe aim of this study is to envisage a streamlined pathological workup to rule out CUPs in patients presenting with MUOs. Sixty-four MUOs were classified using standard histopathology. Clinical data, immunocytochemical markers, and results of molecular analysis were recorded. MUOs were histologically subdivided in clear-cut carcinomas (40 adenocarcinomas, 11 squamous, and 3 neuroendocrine carcinomas) and unclear-carcinoma features (5 undifferentiated and 5 sarcomatoid tumors). Cytohistology of 7/40 adenocarcinomas suggested an early metastatic cancer per se. In 33/40 adenocarcinomas, CK7/CK20 expression pattern, gender, and metastasis sites influenced tissue-specific marker selection. In 23/40 adenocarcinomas, a “putative-immunophenotype” of tissue of origin addressed clinical-diagnostic examinations, identifying 9 early metastatic cancers. Cell lineage markers were used to confirm squamous and neuroendocrine differentiation. Pan-cytokeratins were used to confirm the epithelial nature of poorly differentiated tumors, followed by tissue and cell lineage markers, which identified one melanoma. In total, 47/64 MUOs (73.4%) were confirmed CUP. Molecular analysis, feasible in 37/47 CUPs (78.7%), had no diagnostic impact. Twenty CUP patients, mainly with squamous carcinomas and adenocarcinomas with putative-gynecologic-immunophenotypes, presented with only lymph node metastases and had longer median time to progression and overall survival (< 0.001), compared with patients with other metastatic patterns. We propose a simplified histology-driven workup which could efficiently rule out CUPs and identify early metastatic cancer.
Publisher
Springer Science and Business Media LLC
Subject
Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine
Reference25 articles.
1. Kolling S, Ventre F, Geuna E, Milan M, Pisacane A, Boccaccio C, Sapino A, Montemurro F (2019) “Metastatic Cancer of Unknown Primary” or “Primary Metastatic Cancer”? Front Oncol 9:1546. https://doi.org/10.3389/fonc.2019.01546 2. National Institute for Health and Care Excellence (2019) Metastatic malignant disease of unknown primary origin in adults: diagnosis and management [NICE Guideline No. 104]. https://www.nice.org.uk/guidance/cg104 3. Schofield JB, Oien K (2018) G167 Dataset for histopathological reporting of cancer of unknown primary (CUP) and malignancy of unknown primary origin (MUO) 4. Shen Y, Chu Q, Yin X, He Y, Bai P, Wang Y, Fang W, Timko MP, Fan L, Jiang W (2021) TOD-CUP: a gene expression rank-based majority vote algorithm for tissue origin diagnosis of cancers of unknown primary. Brief Bioinform 22:2106–2118. https://doi.org/10.1093/bib/bbaa031 5. Moran S, Martinez-Cardus A, Sayols S, Musulen E, Balana C, Estival-Gonzalez A, Moutinho C, Heyn H, Diaz-Lagares A, de Moura MC, Stella GM, Comoglio PM, Ruiz-Miro M, Matias-Guiu X, Pazo-Cid R, Anton A, Lopez-Lopez R, Soler G, Longo F, Guerra I, Fernandez S, Assenov Y, Plass C, Morales R, Carles J, Bowtell D, Mileshkin L, Sia D, Tothill R, Tabernero J, Llovet JM, Esteller M (2016) Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol 17:1386–1395. https://doi.org/10.1016/S1470-2045(16)30297-2
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|